Methods and compositions for correction of cardiac...

Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S069100, C435S320100, C435S325000

Reexamination Certificate

active

07494644

ABSTRACT:
The invention provides methods for establishing electrical coupling between cardiomyocytes and recombinant cells which have been genetically engineered to express a connexin protein such as connexin 43 (Cx43) protein. The invention is based on the discovery that genetic modification of skeletal muscle cells to express a recombinant connexin, enables the genetically modified cells to establish electrocommunication with cardiac cells via gap junctions. The recombinant connexin-expressing cells can be used for repair of cardiac tissue and for treatment of cardiac disease by transplantation into cardiac tissue.

REFERENCES:
patent: 5030204 (1991-07-01), Badger et al.
patent: 5087243 (1992-02-01), Avitall
patent: 5103821 (1992-04-01), King
patent: 5130141 (1992-07-01), Law et al.
patent: 5489294 (1996-02-01), McVenes et al.
patent: 5551426 (1996-09-01), Hummel et al.
patent: 5661133 (1997-08-01), Leiden et al.
patent: 5693622 (1997-12-01), Wolff et al.
patent: 5709854 (1998-01-01), Griffith-Cima et al.
patent: 5722403 (1998-03-01), McGee et al.
patent: 6059726 (2000-05-01), Lee et al.
patent: 6086582 (2000-07-01), Altman et al.
patent: 6110161 (2000-08-01), Mathiesen et al.
patent: 6113571 (2000-09-01), Zinger et al.
patent: 6129761 (2000-10-01), Hubbell
patent: 6151525 (2000-11-01), Soykan et al.
patent: 6238429 (2001-05-01), Markowitz et al.
patent: 6239117 (2001-05-01), Christ et al.
patent: 6360749 (2002-03-01), Jayaraman
patent: 6379963 (2002-04-01), Haverich et al.
patent: 6387369 (2002-05-01), Pittenger et al.
patent: 6415178 (2002-07-01), Ben-Haim et al.
patent: 6932804 (2005-08-01), Lee
patent: 7252819 (2007-08-01), Lee
patent: 2001/0009986 (2001-07-01), Ponzi
patent: 2002/0001577 (2002-01-01), Haverich et al.
patent: 2002/0013615 (2002-01-01), Haim et al.
patent: 2002/0031501 (2002-03-01), Law
patent: 2002/0044925 (2002-04-01), Law
patent: 2002/0061295 (2002-05-01), Field
patent: 2002/0061587 (2002-05-01), Anversa
patent: 2002/0081728 (2002-06-01), Haverich et al.
patent: 2003/0104568 (2003-06-01), Lee
patent: 2004/0098075 (2004-05-01), Lee
patent: 2006/0002898 (2006-01-01), Lee et al.
patent: 1152053 (2001-11-01), None
patent: WO 90/10471 (1990-09-01), None
patent: WO 96/18303 (1996-06-01), None
patent: WO9702859 (1997-01-01), None
patent: WO 98/02150 (1998-01-01), None
patent: WO 99/15211 (1999-04-01), None
patent: WO 01/68814 (2001-09-01), None
patent: WO0166472 (2001-09-01), None
patent: 02/19966 (2002-03-01), None
patent: WO 02/33111 (2002-04-01), None
patent: WO03039344 (2003-05-01), None
patent: WO 03/094697 (2003-11-01), None
patent: WO 03/094855 (2003-11-01), None
patent: WO 03/095016 (2003-11-01), None
patent: WO 2004/045709 (2004-06-01), None
patent: WO 2004/050013 (2004-06-01), None
American Heart Association. “2001 Heart and Stroke Statistical Update”, Dallas, TX: American Heart Association, 1999.
Atkins, et al. “Cellular cardiomyoplasty improves diastolic properties of injured heart”,J. Surg. Res., (1999) vol. 85: 234-242.
Atkins, et. al. “Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium”Cardiac and VascularRegeneration, (2000) vol. 1: 43-53.
Atkins, et al. Cardiomyoplasty improves diastolic function in a rabbit model of myocardial injury,Circulation, (1998) vol. 98: Supplement 1: 1227.
Atkins, et. al. “Intracardiac transplantation of skeletal myoblasts yields two populations of striated cells in situ”,Ann Thorac Surg, (1999) vol. 67: 124-129.
Atkins, et al. “Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit heart”,J Heart Lung Transpl., (1999) vol. 18: 43.
Atkins, et al. “Transplanted autologous skeletal myoblasts improve myocardial performance after coronary artery ligation”,Cardiac and Vascular Regeneration, (2000) vol. 1: 76-84.
Balogh, et al. “Expression of gap junction in cultured rat L6 cells during myogenesis”,Developmental Biology, (1993) vol. 155: 351-360.
Blau. “Muscling in on gene therapy”,Nature, (1993) vol. 364: 673-675.
Blau, et al. “Myoblasts in pattern formation and gene therapy”,Trends in Genetics, (1993) vol. 9(8): 269-274.
Brittberg, et al. “Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation”,The New England J of Med., (1994) vol. 331: 889-895.
Chiu. “Cardiac cell transplantation: The autologous skeletal myoblast implantation for myocardial regeneration”,Adv Card Surg, (1999) vol. 11: 69-98.
Chiu, et al. “Cellular cardiomyoplasty: Myocardial regeneration with satellite cell implantation”,Ann Thorac Surg, (1995) vol. 60: 12-18.
Dahl, et al. “Expression of gap junction genes, connexin40 and connexin43, during fetal mouse development”,Anat. Embryol., (1995) vol. 191: 267-278.
Dai, et al. “Gene therapy via primary myoblasts: Long-term expression of factor IX protein following transplantation in vivo”,Proc. Natl. Acad. Sci. USA, vol. 89: 10892-10895. 1992.
Dhawan, et al. “Systemic delivery of human growth hormone by injection of genetically engineered myoblasts”,Science, (1991) vol. 254: 1509-1512.
Dorozynski. “Transplanted cells revive heart muscle”,British Medical Journal, (2000) vol. 321(Issue 7268): 1040-1041.
El Oakley, et al. “Myocyte transplantation for myocardial repair: A few good cells can mend a broken heart”,Ann Thorac Surg. (2001) vol. 71(5): 1724-1733.
Gage, et al. “Genetically modified cells: Applications for intracerebral grafting”,Trends in Neuroscience, (1991) vol. 14(8): 328-333.
GenBank Accession No. AA511201 (Jul. 8, 1997).
GenBank Accession No. AA530689 (Jul. 22, 1997).
GenBank Accession No. AA822279 (Feb. 17, 1998).
GenBank Accession No. AA855990 (Mar. 6, 1998).
GenBank Accession No. AF151980 (Dec. 19, 2000).
GenBank Accession No. AH003191 (Sep. 6, 1995).
GenBank Accession No. M61896 (Mar. 11, 1994).
GenBank Accession No. M65188 (Nov. 1, 1994).
GenBank Accession No. N86403 (Apr. 1, 1996).
GenBank Accession No. NM—000165 (Accession first seen at NCBI on Mar. 24, 1999).
GenBank Accession No. NM—010288 (Accession first seen at NCBI on Jan. 26, 2000).
GenBank Accession No. NM—012567 (Accession first seen at NCBI on Feb. 15, 2000).
GenBank Accession No. X61576 (Nov. 8, 1991).
GenBank Accession No. X62836 (Nov. 7, 1996).
Gussoni, et al. “Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation”,Nature, (1992) vol. 356: 435-438.
Husten. “Global epidemic of cardiovascular disease predicted”,Lancet, (1998) vol. 352: 1530.
Janus, et al. “The modernization of Asia: Implications for coronary heart disease”,Circulation, (1996) vol. 94: 2671-2673.
Kao, et al. “Satellite cell transplantation to repair injured myocardium”,Cardiac and Vascular Regeneration, (2000) vol. 1: 31-42.
Kessler, et al. “Myoblast cell grafting into heart muscle: Cellular biology and potential applications”,Annu Rev Physiol, (1999) vol. 61: 219-242.
Knudsen, et al. “A role for the Ca2+-dependent adhesion molecule, N-cadherin, in myoblast interaction during myogenesis”,Exp. Cell Res., (1990) vol. 188: 175-184.
Koutouzis, et al. “Cell transplantation for central nervous system disorders”,Critical Reviews in Neurobio., (1994) vol. 8(3): 125-162.
Law, et al. “Cell transplantation as an experimental treatment for Duchenne muscular dystrophy”,Transplantation, (1993) vol. 2: 485-505.
Lee, et al. “Coupling requirements for successful impulse propagation with skeletal myocytes transplanted in myocardium”,Annals of Biomedical Engineering, (2000) vol. 28(Supp 1): S54: T6.10.
MacCalman, et al. “Noncoordinate developmental regulation of N-cadherin, N-CAM, integrin, and fibronectin mRNA levels during myoblast terminal differentiation”,Developmental Dynamics, (1992) vol. 195

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Methods and compositions for correction of cardiac... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for correction of cardiac..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for correction of cardiac... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4067818

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.